Pituitary

, Volume 20, Issue 2, pp 261–266 | Cite as

How effective is temozolomide for treating pituitary tumours and when should it be used?

Article

Abstract

Temozolomide (TMZ) has been shown as an effective treatment option in aggressive pituitary adenomas and carcinomas. This review analyses the published case series and demonstrates 42 % of patents show a radiological response and 27 % experience stable disease following TMZ. Prolactinomas and corticotroph tumours respond best to TMZ, showing approximately a 50 % response rate, with non-functioning tumours responding only half as frequently. Other factors that may predict the tumour’s TMZ response include MGMT and MSH status, but neither is sufficiently robust to determine treatment decisions. TMZ has an accepted role in treating pituitary carcinoma and adenomas if radiation and surgery have failed to control tumour growth. To use TMZ on the basis of anticipated future aggression, as a primary therapy, or in preference to radiotherapy remains controversial.

Keywords

Pituitary Temozolomide Review Aggressive Methylguanine-DNA methyltransferase (MGMT) 

References

  1. 1.
    Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella-Branger D, Dufour H et al (2012) Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf) 76(6):769–775CrossRefGoogle Scholar
  2. 2.
    Di Ieva A, Rotondo F, Syro LV, Cusimano MD, Kovacs K (2014) Aggressive pituitary adenomas–diagnosis and emerging treatments. Nat Rev Endocrinol 10(7):423–435CrossRefPubMedGoogle Scholar
  3. 3.
    McCormack AI, Wass JA, Grossman AB (2011) Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest 41(10):1133–1148CrossRefPubMedGoogle Scholar
  4. 4.
    Bengtsson D, Schroder HD, Andersen M, Maiter D, Berinder K, Feldt Rasmussen U et al (2015) Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J Clin Endocrinol Metab 100(4):1689–1698CrossRefPubMedGoogle Scholar
  5. 5.
    Hirohata T, Asano K, Ogawa Y, Takano S, Amano K, Isozaki O et al (2013) DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. J Clin Endocrinol Metab 98(3):1130–1136CrossRefPubMedGoogle Scholar
  6. 6.
    Syro LV, Ortiz LD, Scheithauer BW, Lloyd R, Lau Q, Gonzalez R et al (2011) Treatment of pituitary neoplasms with temozolomide: a review. Cancer 117(3):454–462CrossRefPubMedGoogle Scholar
  7. 7.
    Ortiz LD, Syro LV, Scheithauer BW, Rotondo F, Uribe H, Fadul CE et al (2012) Temozolomide in aggressive pituitary adenomas and carcinomas. Clinics 67(Suppl 1):119–123 (Sao Paulo, Brazil) CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Whitelaw BC, Dworakowska D, Thomas NW, Barazi S, Riordan-Eva P, King AP et al (2012) Temozolomide in the management of dopamine agonist-resistant prolactinomas. Clin Endocrinol (Oxf) 76(6):877–886CrossRefGoogle Scholar
  9. 9.
    Losa M, Bogazzi F, Cannavo S, Ceccato F, Curto L, De Marinis L et al (2016) Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. J Neurooncol 126(3):519–525CrossRefPubMedGoogle Scholar
  10. 10.
    Bruno OD, Juarez-Allen L, Christiansen SB, Manavela M, Danilowicz K, Vigovich C et al (2015) Temozolomide therapy for aggressive pituitary tumors: results in a small series of patients from argentina. Int J Endocrinol Print 2015:587893Google Scholar
  11. 11.
    Losa M, Mazza E, Terreni MR, McCormack A, Gill AJ, Motta M et al (2010) Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol 163(6):843–851CrossRefPubMedGoogle Scholar
  12. 12.
    Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P et al (2010) Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95(10):CrossRefPubMedGoogle Scholar
  13. 13.
    Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA Jr, Vance ML et al (2010) Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 95(11):E280–E290CrossRefPubMedGoogle Scholar
  14. 14.
    Ceccato F, Lombardi G, Manara R, Emanuelli E, Denaro L, Milanese L et al (2015) Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center. J Neurooncol 122(1):189–196CrossRefPubMedGoogle Scholar
  15. 15.
    Chatzellis E, Alexandraki KI, Androulakis II, Kaltsas G (2015) Aggressive pituitary tumors. Neuroendocrinology 101(2):87–104CrossRefPubMedGoogle Scholar
  16. 16.
    Campdera M, Palacios N, Aller J, Magallon R, Martin P, Saucedo G et al (2016) Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment. Pituitary 19(2):158–166CrossRefPubMedGoogle Scholar
  17. 17.
    Marucci G (2011) Treatment of pituitary neoplasms with temozolomide: a review. Cancer 117(17):4101–4102CrossRefPubMedGoogle Scholar
  18. 18.
    Salehi F, Scheithauer BW, Kros JM, Lau Q, Fealey M, Erickson D et al (2011) MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas. J Neurooncol 104(3):647–657CrossRefPubMedGoogle Scholar
  19. 19.
    Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB et al (2007) Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 13(7):2038–2045CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Nguyen SA, Stechishin OD, Luchman HA, Lun XQ, Senger DL, Robbins SM et al (2014) Novel MSH6 mutations in treatment-naive glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation. Clin Cancer Res 20(18):CrossRefPubMedGoogle Scholar
  21. 21.
    Murakami M, Mizutani A, Asano S, Katakami H, Ozawa Y, Yamazaki K et al (2011) A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. Neurosurgery 68(6):E1761–E1767CrossRefPubMedGoogle Scholar
  22. 22.
    Liu JK, Patel J, Eloy JA (2015) The role of temozolomide in the treatment of aggressive pituitary tumors. J Clin Neurosci 22(6):923–929CrossRefPubMedGoogle Scholar
  23. 23.
    Lin AL, Sum MW, DeAngelis LM (2016) Is there a role for early chemotherapy in the management of pituitary adenomas? Neuro-oncology. doi:10.1093/neuonc/now059 PubMedCentralGoogle Scholar
  24. 24.
    Bode H, Seiz M, Lammert A, Brockmann MA, Back W, Hammes H et al (2010) SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Exp Clin Endocrinol Diabetes 118(10):760–763CrossRefPubMedGoogle Scholar
  25. 25.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996CrossRefPubMedGoogle Scholar
  26. 26.
    Mrugala MM, Chamberlain MC (2008) Mechanisms of disease: temozolomide and glioblastoma—look to the future. Nat Clin Pract Oncol 5(8):476–486CrossRefPubMedGoogle Scholar
  27. 27.
    Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN et al (2009) Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol 27(8):1262–1267CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of EndocrinologyKing’s College HospitalLondonUK

Personalised recommendations